Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus best supportive care vs placebo in advanced neuroendocrine tumors of gastrointestinal or lung origin
2011-002887-26Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastrointestinal neuroendocrine neoplasm (GI-NEN) and bronchial neuroendocrine tumor comparing Everolimus plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Progression-free survival. Started Feb 2012; status: completed.
02
Drugs
everolimus
03
Conditions
gastrointestinal neuroendocrine neoplasm (GI-NEN)bronchial neuroendocrine tumor
Beyond the preview
Go deeper on 2011-002887-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002887-26.